Results 61 to 70 of about 37,897 (253)

Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume

Translational Psychiatry, 2017
Lithium and quetiapine are effective treatments for bipolar disorder, but their potential neuroprotective effects in humans remain unclear. A single blinded equivalence randomized controlled maintenance trial was conducted in a prospective cohort of ...
M. Berk, O. Dandash, O. Dandash, R. Daglas, S. Cotton, K. Allott, A. Fornito, C. Suo, P. Klauser, P. Klauser, B. Liberg, B. Liberg, L. Henry, C. Macneil, M. Hasty, P. McGorry, C. Pantelis, M. Yücel   +17 more
semanticscholar   +1 more source

Pharmacological treatment strategies to manage precipitated withdrawal following the administration of buprenorphine in opioid use disorder: A systematic review

Addiction, EarlyView.
Abstract Background and aims There has been limited evidence synthesis examining the treatment of buprenorphine precipitated opioid withdrawal (BPOW). We aimed to conduct the first systematic review to assess the clinical utility of any pharmacological intervention in the management of BPOW.
Emmert Roberts, Nicola Kalk, John Strang
wiley   +1 more source

Phenotype, Management, and Outcomes in Paediatric Acute Pancreatitis: A Real‐Life Cross‐Sectional Study

Acta Paediatrica, EarlyView.
ABSTRACT Aim Limited Canadian data on paediatric acute pancreatitis exist. A meta‐analysis of 48 studies reported equal prevalence of acute pancreatitis among various aetiologies, with rates of severe acute pancreatitis at 13.7% in North America.
Catherine Korman, Doha Elhaoua, Sarah Blain, Thomas Li, Mariam Mohamed, Alessandro David, Colette Deslandres, Ugur Halac, Martha Dirks, Kelly Grzywacz, Michel Lallier, Fernando Alvarez, Prévost Jantchou   +12 more
wiley   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Quetiapine-Induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone

Case Reports in Psychiatry, 2016
The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) can be induced by various conditions, including malignant neoplasms, infections, central nervous system disorders, and numerous drugs.
Theocharis Koufakis
doaj   +1 more source

Pharmacokinetics and adverse effects of a long‐acting IM dopamine agonist: Cabergoline in healthy horses

Equine Veterinary Education, EarlyView.
Summary Background Pituitary pars intermedia dysfunction (PPID) is commonly treated with pergolide mesylate, a dopamine receptor agonist. Cabergoline is a dopamine receptor agonist that has shown activity on prolactin secretion in horses for up to 10 days.
H. Hess, A. Bracken, S. Rao, Y. Nout‐Lomas, D. Gustafson, L. Bass   +5 more
wiley   +1 more source

Successful Clozapine Rechallenge in a 40-Year-Old Male Patient With Paranoid Schizophrenia After Clozapine-Associated Myocarditis. [PDF]

Case Rep Psychiatry
Background Clozapine‐associated myocarditis (CAM) is the most common inflammatory adverse effect under clozapine treatment. In the absence of equally effective therapeutic alternatives for treating treatment‐resistant schizophrenia (TRS), clinicians are often faced with the question of whether to rechallenge clozapine in patients who have experienced ...
Zabel L, Ersek N, Hofmann AB, Machetanz L, Kirchebner J, Stübner S.   +5 more
europepmc   +2 more sources

Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine

Neurology, 2018
Parkinson disease (PD) is a complex neurodegenerative disorder. Cognitive dysfunction and psychosis are leading contributors to nursing home placement.1 Psychosis onset is associated with cognitive decline, levodopa supplementation, and visual ...
Gabriel Moreno, Rhea Gandhi, S. Lessig, Brenton A Wright, I. Litvan, Fatta B. Nahab   +5 more
semanticscholar   +1 more source

Annual Research Review: Psychosis in children and adolescents: key updates from the past 2 decades on psychotic disorders, psychotic experiences, and psychosis risk

Journal of Child Psychology and Psychiatry, Volume 66, Issue 4, Page 460-476, April 2025.
Psychosis in children and adolescents has been studied on a spectrum from (common) psychotic experiences to (rare) early‐onset schizophrenia spectrum disorders. This research review looks at the state‐of‐the‐art for research across the psychosis spectrum, from evidence on psychotic experiences in community and clinical samples of children and ...
Ian Kelleher
wiley   +1 more source

Reversible Hyperkinetic Movement Disorder Related to Quetiapine Withdrawal: A Case Report

Proceedings of Singapore Healthcare, 2010
Quetiapine is used in treatment of schizophrenia, schizoaffective and bipolar disorders as well as psychosis in Parkinson's disease (PD) patients. Neurological side effects are not uncommon with this drug.
Mohammed Tauqeer Ahmad MD, MRCP (London), Chun Wai Yip MBBS, MRCP (UK), Kumar M Prakash MBBS, MRCP (UK)   +2 more
doaj   +1 more source